Alnylam Pharmaceuticals Inc (ALNY) is a Healthcare · Biotechnology company listed on NASDAQ. Price $241.92 (-1.46%), Market cap $39.18B, P/E ratio 73.55, 52-week low–high $284.84 ~ $491.22.
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for
Financial statements, price targets, institutional (13F) holdings and related news for Alnylam Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Alnylam Pharmaceuticals Inc trades at $241.92 (-1.46%). Real-time quotes and charts are available on BlackAll Trade.
Alnylam Pharmaceuticals Inc has a market cap of about $39.18B. Its P/E ratio is 73.55.
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company o